Gosuke Homma

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 13

Top Topics

Peripheral Blood

Top Venues

Pharmaceutical statistics

Clinical trials (London, England)

Biometrical journal. Biometrische Zeitschrift

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Gosuke Homma, Takuma Yoshida
Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes. Pharmaceutical statistics 23 (1) (2023)
Gosuke Homma, Takashi Daimon
Usefulness of the placebo lead-in design for clinical trials with binary outcomes. Clinical trials (London, England) 20 (2) (2023)
Gosuke Homma, Takuma Yoshida
Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes. Pharmaceutical statistics 23 (1) (2023)
Daisuke Yabe, Kosuke Shiki, Gosuke Homma, Thomas Meinicke, Yuji Ogura, Yutaka Seino, null null
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes, obesity & metabolism (2023)
Gosuke Homma, Takashi Daimon
Usefulness of the placebo lead-in design for clinical trials with binary outcomes. Clinical trials (London, England) 20 (2) (2023)
Gosuke Homma, Takuma Yoshida
Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes. Pharmaceutical statistics 23 (1) (2023)
Gosuke Homma, Takashi Daimon
Usefulness of the placebo lead-in design for clinical trials with binary outcomes. Clinical trials (London, England) (2023)
Gosuke Homma, Takashi Daimon
Usefulness of the placebo lead-in design for clinical trials with binary outcomes. Clinical trials (London, England) 20 (2) (2023)
Fumihiko Sakai, Takao Takeshima, Gosuke Homma, Yuka Tanji, Hideaki Katagiri, Mika Komori
Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61 (5) (2021)
Kensei Yamaguchi, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Yoshito Komatsu, Tomohiro Nishina, Yasushi Omuro, Takao Tamura, Yongzhe Piao, Gosuke Homma, Min-Hua Jen, Astra M Liepa, Kei Muro
Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. Clinical drug investigation 41 (1) (2020)
Gosuke Homma, Takashi Daimon
Sequential parallel comparison design for "gold standard" noninferiority trials with a prespecified margin. Biometrical journal. Biometrische Zeitschrift 61 (6) (2019)
Gosuke Homma, Takashi Daimon
Sequential parallel comparison design with two coprimary endpoints. Pharmaceutical statistics 19 (3) (2019)
Gosuke Homma, Takashi Daimon
A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomes. Pharmaceutical statistics 18 (2) (2018)